• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人疱疹病毒8型衍生的病毒白细胞介素6在卡波西肉瘤细胞中诱导PTX3表达。

Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells.

作者信息

Klouche Mariam, Brockmeyer Norbert, Knabbe Cornelius, Rose-John Stefan

机构信息

Institute of Clinical Pathology, Department of Laboratory Medicine, Robert Bosch Hospital and Robert Bosch Society for Medical Research, Stuttgart, Germany.

出版信息

AIDS. 2002 May 24;16(8):F9-18. doi: 10.1097/00002030-200205240-00001.

DOI:10.1097/00002030-200205240-00001
PMID:12004288
Abstract

OBJECTIVE

To analyse if human herpesvirus 8 (HHV8)-derived viral interleukin-6 (vIL-6) has the capacity to activate Kaposi's sarcoma (KS) cells to elicit a local acute-phase response.

DESIGN

Proinflammatory activation of KS cells was compared using vIL-6, human IL-6, as well as the complex of human IL-6 with the soluble IL-6 receptor, and expression of the novel acute-phase protein pentraxin-3 (PTX3) was analysed.

METHODS

We established primary KS cell cultures from patients with AIDS-associated and classical KS and expressed recombinant HHV8-derived vIL-6 in COS-7 cells. Expression of PTX3 by vIL-6-stimulated KS cell cultures was analysed by quantitative real-time reverse transcriptase-polymerase chain reaction. Mitogenic effects of vIL-6 on the KS cells of distinct aetiology were compared by [3H]thymidine incorporation.

RESULTS

We show that vIL-6 induced a marked and sustained expression of the novel acute-phase protein PTX3 in human primary KS cell cultures. vIL-6 directly activated KS cells, which uniquely expressed gp130, the signal-transducing subunit of the IL-6 receptor, but were negative for the IL-6-binding unit (IL-6R). In contrast, human IL-6 did not stimulate KS cells in the absence of the full IL-6R. Expression of PTX3 messenger RNA increased by more than 25-fold in vIL-6-stimulated KS cells after 24 h. Particularly after extended incubation with the virokine, vIL-6 mediated a pronounced mitogenic effect on KS cells.

CONCLUSION

The induction of an extrahepatic acute-phase response by vIL-6-activated KS cells may contribute to local tissue damage and the attraction of inflammatory cells, and add to a more aggressive phenotype.

摘要

目的

分析人疱疹病毒8型(HHV8)衍生的病毒白细胞介素-6(vIL-6)是否有能力激活卡波西肉瘤(KS)细胞以引发局部急性期反应。

设计

使用vIL-6、人白细胞介素-6以及人白细胞介素-6与可溶性白细胞介素-6受体的复合物比较KS细胞的促炎激活,并分析新型急性期蛋白五聚素-3(PTX3)的表达。

方法

我们从艾滋病相关型和经典型KS患者中建立了原代KS细胞培养物,并在COS-7细胞中表达重组HHV8衍生的vIL-6。通过定量实时逆转录聚合酶链反应分析vIL-6刺激的KS细胞培养物中PTX3的表达。通过[3H]胸苷掺入比较vIL-6对不同病因的KS细胞的促有丝分裂作用。

结果

我们表明,vIL-6在人原代KS细胞培养物中诱导了新型急性期蛋白PTX3的显著且持续的表达。vIL-6直接激活KS细胞,这些细胞独特地表达gp130,即白细胞介素-6受体的信号转导亚基,但白细胞介素-6结合单位(IL-6R)呈阴性。相比之下,在没有完整白细胞介素-6受体的情况下,人白细胞介素-6不会刺激KS细胞。24小时后,vIL-6刺激的KS细胞中PTX3信使核糖核酸的表达增加了25倍以上。特别是在与这种病毒因子长时间孵育后,vIL-6对KS细胞介导了明显的促有丝分裂作用。

结论

vIL-6激活的KS细胞诱导肝外急性期反应可能导致局部组织损伤和炎症细胞的吸引,并加重更具侵袭性的表型。

相似文献

1
Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells.人疱疹病毒8型衍生的病毒白细胞介素6在卡波西肉瘤细胞中诱导PTX3表达。
AIDS. 2002 May 24;16(8):F9-18. doi: 10.1097/00002030-200205240-00001.
2
Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6.人疱疹病毒8型白细胞介素-6(vIL-6)通过gp130发出信号,但具有与人类IL-6不同的结构和受体结合特性。
J Virol. 1999 Oct;73(10):8268-78. doi: 10.1128/JVI.73.10.8268-8278.1999.
3
IL-6 receptor independent stimulation of human gp130 by viral IL-6.病毒白细胞介素-6对人gp130的白细胞介素-6受体非依赖性刺激
J Immunol. 2000 May 1;164(9):4672-7. doi: 10.4049/jimmunol.164.9.4672.
4
Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.检测人类疱疹病毒8编码的白细胞介素-6(vIL-6)与gp130和白细胞介素-6受体(IL-6R)的直接结合,并鉴定vIL-6中对IL-6R依赖性和非依赖性信号传导重要的氨基酸残基。
J Virol. 2001 Apr;75(7):3325-34. doi: 10.1128/JVI.75.7.3325-3334.2001.
5
The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.白细胞介素-6受体的可溶性形式(sIL-6Rα)是艾滋病相关卡波西肉瘤(KS)细胞的一种强效生长因子;gp130的可溶性形式对sIL-6Rα诱导的艾滋病相关卡波西肉瘤细胞生长具有拮抗作用。
Int Immunol. 1996 Apr;8(4):595-602. doi: 10.1093/intimm/8.4.595.
6
Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells.人类疱疹病毒8白细胞介素-6同源物可激活神经元和造血细胞上的gp130。
Eur J Biochem. 2000 Jun;267(12):3604-12. doi: 10.1046/j.1432-1327.2000.01389.x.
7
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.人白细胞介素-6与卡波西肉瘤相关疱疹病毒编码的病毒白细胞介素-6触发的信号级联反应的特征分析
Clin Cancer Res. 2000 Mar;6(3):1180-9.
8
Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus.卡波西肉瘤相关疱疹病毒编码的病毒白细胞介素-6与受体的结合。
Blood. 2001 Nov 15;98(10):3042-9. doi: 10.1182/blood.v98.10.3042.
9
Genetic Analyses of Contributions of Viral Interleukin-6 Interactions and Signaling to Human Herpesvirus 8 Productive Replication.病毒白细胞介素-6 相互作用和信号对人类疱疹病毒 8 有效复制的贡献的遗传分析。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00909-20.
10
Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6.病毒模拟人类细胞因子的分子机制:人疱疹病毒8型白细胞介素-6对gp130的激活
J Mol Biol. 2004 Jan 9;335(2):641-54. doi: 10.1016/j.jmb.2003.10.070.

引用本文的文献

1
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.白细胞介素 6 转导信号通过可溶性白细胞介素 6 受体:对白细胞介素 6 促炎活性的重要性。
Int J Biol Sci. 2012;8(9):1237-47. doi: 10.7150/ijbs.4989. Epub 2012 Oct 24.
2
Pathogen recognition by the long pentraxin PTX3.长五聚体蛋白PTX3对病原体的识别
J Biomed Biotechnol. 2011;2011:830421. doi: 10.1155/2011/830421. Epub 2011 Jun 2.
3
Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case.
HIV 阴性免疫功能正常患者的卡波西肉瘤疱疹病毒相关噬血细胞性综合征并发多中心 Castleman 病和卡波西肉瘤:一例尸检病例。
J Korean Med Sci. 2009 Oct;24(5):970-4. doi: 10.3346/jkms.2009.24.5.970. Epub 2009 Sep 24.
4
Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.卡波西肉瘤相关疱疹病毒的病毒白细胞介素-6表达的阻断
Mol Cancer Ther. 2008 Mar;7(3):712-20. doi: 10.1158/1535-7163.MCT-07-2036.
5
Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3.固有免疫中的五聚体蛋白:从C反应蛋白到长链五聚体蛋白PTX3
J Clin Immunol. 2008 Jan;28(1):1-13. doi: 10.1007/s10875-007-9126-7. Epub 2007 Sep 9.
6
Molecular biology of KSHV in relation to AIDS-associated oncogenesis.与艾滋病相关肿瘤发生相关的卡波西肉瘤相关疱疹病毒分子生物学
Cancer Treat Res. 2007;133:69-127. doi: 10.1007/978-0-387-46816-7_3.
7
Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus.卡波西肉瘤相关疱疹病毒K15蛋白对宿主基因表达的调控
J Virol. 2007 Jan;81(1):42-58. doi: 10.1128/JVI.00648-06. Epub 2006 Oct 18.
8
Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6.人类疱疹病毒8型白细胞介素-6(vIL-6)中gp80独立性的结构要求以及vIL-6诱导的gp130信号复合物中gp80稳定化的证据。
J Virol. 2006 Oct;80(19):9811-21. doi: 10.1128/JVI.00872-06.
9
Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display.通过细胞内滞留以及用噬菌体展示筛选出的抗病毒白细胞介素-6(vIL-6)单链抗体中和vIL-6,从而废除vIL-6诱导的信号传导。
J Virol. 2006 Sep;80(17):8510-20. doi: 10.1128/JVI.00420-06.
10
Common and unique gene expression signatures of human macrophages in response to four strains of Mycobacterium avium that differ in their growth and persistence characteristics.人类巨噬细胞对四株生长和持续特性不同的鸟分枝杆菌产生应答时的常见和独特基因表达特征。
Infect Immun. 2005 Jun;73(6):3330-41. doi: 10.1128/IAI.73.6.3330-3341.2005.